The Cooper Companies
COO
$60.94
+2.23%
The Cooper Companies, Inc. is a leading global eyecare and women's health company operating through two primary segments: CooperVision, a major contact lens manufacturer, and CooperSurgical, which focuses on fertility, reproductive care, and women's health medical devices. The company is a distinct market leader, controlling roughly one-fourth of the U.S. contact lens market with its comprehensive portfolio of specialty lenses and holding a significant share of the U.S. IUD market with its hormone-free Paragard product. The current investor narrative revolves around navigating a challenging market environment, as recent sharp stock price declines suggest concerns over potential growth deceleration, margin pressures, or competitive dynamics within its core healthcare markets, despite its established competitive positions.…
COO
The Cooper Companies
$60.94
Related headlines
Investment Opinion: Should I buy COO Today?
Rating & Thesis: COO is a Hold. The stock presents a conflicted picture where strong financials and an attractive forward valuation are overshadowed by deteriorating momentum, volatile fundamentals, and a lack of clear near-term catalysts, warranting a neutral stance until operational consistency improves.
Supporting Evidence: The forward P/E of 11.9x is compelling and suggests significant earnings growth is priced in. The company's balance sheet is robust with a debt-to-equity ratio of 0.34 and a current ratio of 1.89. TTM free cash flow of $491.2 million provides ample financial flexibility. However, these positives are counterbalanced by a trailing P/E of 37.3x that remains elevated, recent revenue growth of just 6.16%, and severe gross margin volatility from 56.4% to 67.9% in consecutive quarters.
Risks & Conditions: The two biggest risks are sustained margin pressure and further growth deceleration. This Hold rating would upgrade to a Buy if the stock demonstrates two consecutive quarters of gross margin stability above 65% coupled with revenue growth re-accelerating above 8% YoY. It would downgrade to a Sell if the stock breaks below its 52-week low of $58.89 on high volume and Q2 2026 results show gross margin falling back below 60%. Relative to its own history and the implied forward earnings, the stock appears fairly valued to slightly undervalued, but the premium trailing multiple indicates the market is still pricing in a high degree of uncertainty.
Sign up to view all
COO 12-Month Price Forecast
The assessment is neutral with medium confidence. The valuation story is bifurcated: the forward P/E is very attractive, but it is predicated on earnings stabilizing after recent volatility. The strong cash flow and balance sheet provide a margin of safety, but the technical picture is dire and reflects deep-seated concerns about growth and margins. The stance would upgrade to bullish on evidence of sustained margin recovery (e.g., two quarters >65%) and would turn bearish if the stock breaks key support at $58.89 on deteriorating fundamentals. The high probability base case reflects a 'show me' story where the stock languishes until management proves it can deliver consistent results.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cooper Companies's 12-month outlook, with a consensus price target around $79.22 and implied upside of +30.0% versus the current price.
Average Target
$79.22
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$49 - $79
Analyst target range
Analyst coverage for COO appears limited, with only 4 analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the dataset. This indicates insufficient analyst coverage to derive a meaningful consensus view. Limited coverage is typical for mid-cap companies and can lead to higher volatility and less efficient price discovery, as the stock may not be on the radar of major institutional research desks. The available institutional ratings show a mixed but generally stable picture among the firms that do cover it, with recent actions from Citigroup (Neutral), Needham (Buy), and Barclays (Overweight) all maintaining their existing stances. The lack of a broad analyst target range means investors have less external validation for fair value, placing greater emphasis on independent fundamental and valuation analysis to gauge the investment thesis amidst the stock's significant downturn.
Bulls vs Bears: COO Investment Factors
The evidence currently tilts bearish, as fundamental concerns over growth deceleration and margin volatility appear to be driving the severe price decline, outweighing the bullish case built on financial strength and valuation. The bearish points are more immediate and reflective of deteriorating operational performance, while the bullish points are longer-term structural strengths. The single most important tension in the investment debate is whether the company's recent margin recovery and 6.16% revenue growth represent a sustainable stabilization or a temporary respite before further fundamental erosion. If margins stabilize near 68% and growth re-accelerates, the low forward P/E will look compelling; if not, the high trailing P/E suggests further multiple compression is likely.
Bullish
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $491.2 million. This provides significant internal funding for growth, debt reduction, and potential shareholder returns, underpinning financial stability despite the stock's decline.
- Healthy Balance Sheet with Low Debt: COO maintains a conservative debt-to-equity ratio of 0.34 and a strong current ratio of 1.89. This low leverage provides a cushion against market downturns and operational headwinds, reducing financial risk.
- Attractive Forward P/E Valuation: The forward P/E ratio of 11.9x is significantly lower than the trailing P/E of 37.3x, indicating the market expects a sharp earnings recovery. This forward multiple suggests the stock may be undervalued if earnings projections materialize.
- Technical Oversold Condition: The stock is trading at $59.61, just 0.2% above its 52-week low of $58.89, following a 26.81% decline over the past year. This extreme oversold condition, with a relative strength of -52.00 vs. the S&P 500, suggests a potential technical rebound if sentiment improves.
Bearish
- Severe Revenue Growth Deceleration: Recent quarterly revenue growth has slowed to 6.16% YoY in Q1 2026, down from prior quarters. This deceleration raises concerns about demand sustainability in both the contact lens and fertility markets, challenging the growth narrative.
- Extreme Profit Margin Volatility: Gross margin swung wildly from 67.9% in Q1 2026 to 56.4% in Q4 2025, while net margin fluctuated from 12.8% to 7.9% over the same period. This inconsistency suggests underlying cost pressures or pricing issues, undermining earnings quality and predictability.
- Elevated Trailing P/E Despite Crash: Even after the steep price decline, the trailing P/E of 37.3x remains elevated historically and is likely a premium to industry peers. This high multiple indicates the stock was previously priced for perfection, and the crash may be a valuation reset as growth moderates.
- Negative Momentum and Weak Relative Strength: The stock is down 15.19% over the past month and 28.17% over three months, with a relative strength of -52.00 versus the S&P 500 over one year. This persistent negative momentum reflects a complete breakdown in investor confidence that may not reverse quickly.
COO Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 26.81% over the past year. With a current price of $59.61, it is trading near the very bottom of its 52-week range of $58.89 to $89.83, positioning it at just 0.2% above its 52-week low. This extreme positioning suggests the stock is deeply oversold and may present a value opportunity, but it also risks being a 'falling knife' if fundamental headwinds persist. Recent momentum is decisively negative and accelerating the longer-term downtrend, with the stock down 15.19% over the past month and 28.17% over the past three months. This severe underperformance is starkly highlighted by a relative strength of -52.00 versus the S&P 500 over one year, indicating a complete breakdown in investor confidence. Key technical levels are clearly defined, with immediate support at the 52-week low of $58.89 and major resistance at the 52-week high of $89.83. A breakdown below $58.89 could trigger further technical selling, while any recovery would need to overcome significant overhead supply. The stock's beta of 0.894 indicates it has been slightly less volatile than the broader market during this decline, which is unusual for a stock in freefall and may point to a lack of aggressive selling pressure from systematic or momentum-driven funds.
Beta
0.89
0.89x market volatility
Max Drawdown
-30.1%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-26.5%
Cumulative gain past year
| Period | COO Return | S&P 500 |
|---|---|---|
| 1m | -13.0% | +4.0% |
| 3m | -25.6% | +8.2% |
| 6m | -15.5% | +11.5% |
| 1y | -26.5% | +24.3% |
| ytd | -24.9% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COO Fundamental Analysis
Revenue growth has shown signs of deceleration and inconsistency. The most recent quarterly revenue (Q1 2026) was $1.024 billion, representing a year-over-year growth of 6.16%. However, this follows a prior quarter (Q4 2025) where revenue was slightly higher at $1.065 billion but gross margin compressed sharply to 56.4%. Segment data indicates the CooperVision segment drove the majority of sales at $695.1 million, compared to $329.0 million for CooperSurgical. The trajectory suggests growth is moderating from stronger levels seen in previous quarters, raising questions about near-term demand. The company remains profitable but has experienced significant margin volatility. Net income for Q1 2026 was $130.8 million, yielding a net margin of 12.8%, which is a recovery from the prior quarter's net income of $84.6 million and net margin of 7.9%. Gross margin rebounded strongly to 67.9% in Q1 2026 from 56.4% in Q4 2025, indicating potential one-time cost issues or pricing actions. This fluctuation in profitability, against a backdrop of high operating expenses, introduces uncertainty into earnings quality. The balance sheet is healthy with a strong liquidity position and manageable debt levels. The current ratio is a robust 1.89, indicating ample short-term assets to cover liabilities. The debt-to-equity ratio is a conservative 0.34, reflecting a low reliance on debt financing. Most importantly, the company generates substantial cash, with trailing twelve-month free cash flow of $491.2 million, providing significant internal funding capacity for operations, growth investments, and potential shareholder returns without financial strain.
Quarterly Revenue
$1.0B
2026-01
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$491200000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COO Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E is elevated at 37.3x, while the forward P/E is significantly lower at 11.9x. This substantial gap implies the market expects a sharp recovery in earnings over the next twelve months, likely pricing in a rebound from the volatile profitability seen in recent quarters. Compared to industry averages, the stock's trailing P/E of 37.3x likely represents a significant premium, though specific industry average data is not provided in the inputs. This premium would need to be justified by superior growth prospects or market positioning, which is currently under scrutiny given the stock's performance. Historically, the current trailing P/E of 37.3x sits above the levels seen in recent quarters (e.g., 30.6x in Q1 2026, 40.9x in Q4 2025), suggesting that even after the price decline, the valuation is not at a historical low point on an earnings basis. This indicates the market had previously priced in very high expectations, and the recent crash may be a correction of those optimistic multiples as fundamentals have softened.
PE
37.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~119x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is extreme margin volatility, as evidenced by the 11.5 percentage point swing in gross margin between Q4 2025 (56.4%) and Q1 2026 (67.9%). This inconsistency makes earnings highly unpredictable. Furthermore, revenue growth has decelerated to 6.16% YoY, raising concerns about the company's ability to sustain top-line expansion to justify its still-elevated trailing P/E of 37.3x. While the balance sheet is strong, the company's valuation remains dependent on a sharp earnings rebound implied by the forward P/E of 11.9x, creating execution risk.
Market & Competitive Risks: The stock faces significant valuation compression risk, as its trailing P/E of 37.3x is historically high for the company and likely a premium to the medical instruments sector. With a beta of 0.894, the stock has shown less volatility than the market during its decline, but its severe underperformance (-52.00 relative strength) indicates intense company-specific selling pressure. Competitive risks include potential market share erosion in the contact lens segment (where it holds ~25% share) and the fertility market, which could be sensitive to economic cycles and regulatory changes affecting reproductive care.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, where margin volatility persists, revenue growth stalls or turns negative, and the forward earnings rebound fails to materialize. This could trigger a further de-rating of the multiple towards historical lows. The realistic downside is to the 52-week low of $58.89, representing a -1.2% decline from the current $59.61. However, a break below this technical support could lead to a fall towards the $50-$55 range, representing a potential -15% to -20% loss from current levels, especially if the broader market enters a correction and investors continue to flee stocks with questionable near-term growth profiles.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Extreme profit margin volatility, as seen in the gross margin swing from 56.4% to 67.9%, makes future earnings highly unpredictable. 2) Growth Risk: Revenue growth has decelerated to 6.16% YoY, raising doubts about the company's growth trajectory. 3) Valuation Risk: The elevated trailing P/E of 37.3x leaves the stock vulnerable to further multiple compression if growth stalls. 4) Market Risk: With limited analyst coverage, the stock suffers from lower visibility and can experience heightened volatility during market downturns.
The 12-month forecast for COO is a wide range reflecting high uncertainty, with a base case target of $62-$70 (55% probability). This assumes the company stabilizes with mid-single-digit growth and moderate margin volatility. The bull case target is $78-$85 (25% probability), requiring a successful operational turnaround and re-acceleration of growth. The bear case target is $50-$58 (20% probability), which would occur if fundamentals deteriorate further. The most likely scenario is the base case, where the stock consolidates at depressed levels until management demonstrates consistent execution over multiple quarters.
COO's valuation is a tale of two metrics, making it fairly valued with a skew towards potential undervaluation. The trailing P/E of 37.3x is elevated and suggests the stock is still expensive based on recent earnings, which were volatile. However, the forward P/E of 11.9x is low and implies the market expects a dramatic earnings recovery. This gap indicates the stock is undervalued if forward estimates are met, but those estimates carry high uncertainty. Compared to its own 52-week high, the stock is deeply undervalued, but relative to its erratic fundamentals, the valuation appears fair.
COO is a speculative buy for value investors with a high risk tolerance. The forward P/E of 11.9x is very attractive and suggests significant upside if earnings recover as projected. However, it comes with substantial risk, given the stock's 26.81% decline over the past year, severe margin volatility, and decelerating revenue growth. It could be a good buy for investors who believe the company's market leadership and strong cash flow ($491.2M TTM) will allow it to navigate current headwinds, but it is not suitable for conservative investors seeking stability.
COO is more suitable for a long-term investment horizon of 2-3 years, not short-term trading. The investment thesis is based on a potential operational turnaround and valuation normalization, which will take multiple quarters to unfold. The stock's high volatility (evident in its recent crash) and lack of a dividend make it poor for income or short-term stability. Patient investors can use the current low price to build a position, but they must be prepared for further volatility and have the horizon to wait for the company's fundamentals to improve and for the market to recognize that value.
